Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-28T16:25:53.988Z Has data issue: false hasContentIssue false
  • English
  • Français

Serum matrix metalloproteinases and tympanosclerosis

Published online by Cambridge University Press:  19 October 2010

H Aslan ,
M Sinan Başoğlu ,
B Şentürk ,
C Özbay ,
H Katilmiş  and
S Öztürkcan
H Aslan*
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Atatürk Research and Training Hospital, Ministry of Health, İzmir, Turkey
M Sinan Başoğlu
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Atatürk Research and Training Hospital, Ministry of Health, İzmir, Turkey
B Şentürk
Affiliation:
Department of Biochemistry, Atatürk Research and Training Hospital, Ministry of Health, İzmir, Turkey
C Özbay
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Atatürk Research and Training Hospital, Ministry of Health, İzmir, Turkey
H Katilmiş
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Atatürk Research and Training Hospital, Ministry of Health, İzmir, Turkey
S Öztürkcan
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Atatürk Research and Training Hospital, Ministry of Health, İzmir, Turkey
*
Address for correspondence: Op Dr Hale Aslan, Kasırga Sok 22/1, Özyıldırım Sitesi B blok K:8 D:18, Balçova, İzmir, Turkey Fax: +90 232 2431530 E-mail: drhaleaslan@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim:

To investigate levels of matrix metalloproteinases 2 and 9, and of their tissue inhibitor (i.e. tissue inhibitor matrix metalloproteinase 1), in the serum of patients with tympanosclerosis.

Materials and method:

We included 40 patients (age range 13–63 years) who had undergone surgery in the ENT department of İzmir Atatürk Training and Research Hospital between 2002 and 2007. Twenty had uncomplicated chronic otitis media and 20 had tympanosclerosis. We also included as the control group 20 individuals with no history of previous otic complaints or systemic or infectious disease. Serum levels of serum matrix metalloproteinases 2 and 9 and of tissue inhibitor matrix metalloproteinase 1 were measured in all subjects and compared.

Result:

Significantly higher levels of serum matrix metalloproteinases 2 and 9 were found in the tympanosclerosis group, compared with the chronic otitis media and control groups. There was no statistically significant difference in tissue inhibitor matrix metalloproteinase 1 level between the three groups.

Conclusion:

Tympanosclerosis surgery has poor success rates, since the pathological process is still active. We suggest that high levels of matrix metalloproteinases may play a role in the continuation of the disease process.

Keywords

TympanosclerosisEtiologySerumMatrix Metalloproteinase
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 125 , Issue 2 , February 2011 , pp. 142 - 146
Copyright
Copyright © JLO (1984) Limited 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Egeblad, M, Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–74CrossRefGoogle ScholarPubMed
2Yoon, SO, Park, SJ, Yun, CH, Chung, AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128–37Google ScholarPubMed
3Doğu, F, Yıldıran, A, Güloğlu, D, Çipe, F, Yüksek, M, Babacan, E et al. Serum transforming growth factor beta(TGF-B), matrix metallopreoteinase-2(MMP-2), matrix metalloproteinase-9(MMP-9) and tissue inhibitor of metalloproteinase(TIMP-1) levels in childhood asthma. Turk J Med Sci 2008;38:415–19Google Scholar
4Pirodda, A, Feri, G, Bruzzi, C, Marini, M, Faggioli, GL. Possible relationship between tympanosclerosis and atherosclerosis. Acta Otolaryngol 2004;124:574–6CrossRefGoogle ScholarPubMed
5Van Wart, HE, Birkadel-Hansen, H. The cysteine switch: a principle of regulation of metalloproteinase gene family. Proc Natl Acad Sci U S A 1990;87:5578–82CrossRefGoogle ScholarPubMed
6Valentin, F, Bueb, JL, Kieffer, P, Tschirhart, E, Atkinson, J. Oxidative stress activates matrix metalloproteinase 2 in cultured human coronary smooth muscle cells. Fundam Clin Pharmacol 2005;19:661–7CrossRefGoogle ScholarPubMed
7Mattson, C, Magnuson, K, Hellström, S. Myringotomy: a prerequisite for the development of myringosclerosis. Laryngoscope 1998;108:102–6CrossRefGoogle Scholar
8Jennings, CR, Guo, L, Collins, HM, Birchall, JP. Matrix metalloproteinases 2 and 9 in otitis media with effusion. Clin Otolaryngol Allied Sci 2001;26:491–4CrossRefGoogle ScholarPubMed
9Antonelli, Pj, Schultz, GS, Kim, KM, Cantwell, JS, Sundin, DJ, Pemberton, PA. Alpha1-antitripsin and ilomastat inhibit inflamatory proteases present in human middle ear effusions. Laryngoscope 2003;113:1347–51CrossRefGoogle Scholar
10Gomez, DE, Alonso, DF, Yoshiji, H, Thorgeirsson, UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111–22Google ScholarPubMed
11Moon, SK, Linthicum, FH, Yang, HD, Lee, SJ, Park, K. Activities of matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in idiopathic hemathympanum and otitis media with effusion. Acta Otolaryngol 2008;128:144–50CrossRefGoogle ScholarPubMed
12Wilmoth, JG, Schultz, GS, Antonelli, PJ. Tympanic membrane metalloproteinase inflamatory response. Otolaryngol Head Neck Surg 2003;129:647–54CrossRefGoogle Scholar
13De, S, Fenton, JE, Jones, AS. Matrix metalloproteinases and their inhibitors in nonneoplastic otorhinolaryngological disease. J Laryngol Otol 2005;119:436–42CrossRefGoogle ScholarPubMed
14Duerr, S, Wendler, O, Aigner, T, Karosi, S, Schick, B. Metalloproteinases in juvenil angiofibroma - a collagen rich tumor. Hum Pathol 2008;39:259–68CrossRefGoogle Scholar
15Longo, GM, Xiong, W, Grenier, TC, Zhao, Y, Fiotti, N, Baxter, BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625–32CrossRefGoogle ScholarPubMed
16Ducharme, A, Frantz, S, Aikawa, M, Rabkin, E, Lindsey, M, Rohde, LE et al. Targeted deletion of matrix metalloproteinases 9 attenuates left ventriculer enlargment and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55–62CrossRefGoogle Scholar
17Luttun, A, Lutgens, E, Manderveld, A, Maris, K, Collen, D, Carmeliet, P et al. Loss of matrix metalloproteinase 9 or matrix metallproteinase 12 protects apolipoprotein-E deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004;109:1408–14CrossRefGoogle ScholarPubMed
18Yasmin, , McEniery, CM, Wallace, S, Dakham, Z, Pulsakar, P, Maki-Petaja, K, Ashby, MJ, Cockroft, JR, Wilkinson, IB. Matrix metalloproteinase 9, matrix metalloproteinase 2 and serum elastase activity are associated with systolic hypertension and arterial stifness. Arterioscler Thromb Vasc Biol 2005;25:372–8CrossRefGoogle Scholar
19Koç, A, Üneri, C. Genetic predisposition for tympanosclerosic degeneration. Eur Arch Otorhinolaryngol 2002;259:180–3CrossRefGoogle ScholarPubMed
20Ravaud, P, Moulinier, L, Giraudeau, B. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis Rheum 1999;42:475–823.0.CO;2-S>CrossRefGoogle ScholarPubMed
21Cohen, H, Solomon, V, Alferiev, IS. Bisphosphanates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm Res 1998;15:606–13CrossRefGoogle Scholar
22Brandt, KD, Yu, LP, Amith, G. Therapeutic effect of doxycycline in canine osteoarthritis. Osteoarthritis Cartilage 1993;1:14Google Scholar
23Axisa, B, Loftus, IM, Naylor, AM, Goodall, S, Jones, L, Bell, PRF et al. Prospective, randomized, double-blinded trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002;33:2858–64CrossRefGoogle ScholarPubMed
24Ozcan, İ, Selcuk, A, Ozcan, KM, Akdogan, O, Giray, SG, Dere, H et al. The effect of topical doxycycline in the prevention of experimental thympanosclerosis. Laryngoscope 2008;118:1051–6CrossRefGoogle Scholar
25Uneri, C, Bağlam, T, Yazıcı, M. The effect of vitamin E treatment on the development of myringosclerosis after ventilation tube insertion. Int J Pediatr Otorhinolaryngol 2006;70:1045–8CrossRefGoogle ScholarPubMed
26Papadopoulos, DP, Economou, EV, Makris, TK, Kapetanios, KJ, Moyssakis, I, Votteas, VE et al. Effect of angiotensin converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction. Drugs Exp Clin Res 2004;30:55–65Google ScholarPubMed
27Murray, GI, Duncan, MI, O'Neil, P, Melvin, WT, Fothergill, JE. Matrix metalloproteinase 1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461–2CrossRefGoogle ScholarPubMed
28Kallakury, BVS, Karikehalli, S, Haholu, A, Sheehan, CE, Azumi, N, Ross, JS. Increased expression of matrix metalloproteinase 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clinical Cancer Research 2001;7:3113–19Google ScholarPubMed